Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: breast cancer + longer survival + taxotere  Related to the article below (Last Update: 5/5/2008)

Weekly Doses of Taxol Prolonged Lives of Breast Cancer Patients
U.S. News & World Report, DC - Apr 16, 2008
There were no significant differences in survival between those treated with Taxol and those treated with Taxotere or between the groups treated weekly or ...
Women With Breast Cancer Gain Benefit From Weekly Chemotherapy
Bloomberg - Apr 16, 2008
Taxotere slowed the cancer's return regardless of when it was given, though it didn't prolong survival, the study found. ``This study shows giving ...
Weekly Taxol best for followup breast cancer care
Reuters - Apr 16, 2008
By Gene Emery BOSTON, April 16 (Reuters) - Women whose breast cancer may have spread survive a bit longer with weekly infusions of the drug Taxol than ...
Source: Google News

… Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results -
JO'Shaughnessy, D Miles, S Vukelja, V Moiseyenko, … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org
... median time to dose reduction was longer in the ... development for patients with breast
cancer whose disease ... to provide superior overall survival compared with ...

… and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a … -
JM Nabholtz, C Falkson, D Campos, J Szanto, M … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... Falkson G, Tormey DC, Carey P, et al: Long-term survival of patients ... V, et al: Cytotoxic
and hormonal treatment for metastatic breast cancer: A systematic ...

… of patients with complete remission following combination chemotherapy for metastatic breast cancer -
PA Greenberg, GN Hortobagyi, TL Smith, LD Ziegler, … - Journal of Clinical Oncology, 1996 - jco.ascopubs.org
... AD Ho Characteristics associated with long-term progression-free survival following
high ... dose chemotherapy in metastatic breast cancer and influence ...

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer -
JL Blum, SE Jones, AU Buzdar, PM LoRusso, I Kuter, … - Journal of Clinical Oncology, 1999 - jcojournal.org
... median survival time (384 days) was surprisingly long. ... studies of paclitaxel-refractory
breast cancer patients are ... 14 The median survival times obtained with ...

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer -
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown … - Journal of Clinical Oncology, 1998 - jco.ascopubs.org
... and IA Olivotto Impact on Survival of Time ... far-advanced or inflammatory breast cancer
with fixed ... chemotherapy, surgery, and radiotherapy: long-term results. ...

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer … -
GM Clark, GW Sledge Jr, CK Osborne, WL McGuire - Journal of Clinical Oncology, 1987 - jcojournal.org
... each metastatic site, receptor-positive patients had longer survival. ... the Role of
Bisphosphonates in Breast Cancer J. Clin ... Efficacy and Safety of Docetaxel in a ...

… mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous … -
JM Nabholtz, HJ Senn, WR Bezwoda, D Melnychuk, L … - J Clin Oncol, 1999 - ncbi.nlm.nih.gov
... MV) in patients with metastatic breast cancer (MBC) progressing ... time to progression
(TTP) and overall survival were significantly longer with docetaxel ...

… Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous … -
JM Nabholtz, HJ Senn, WR Bezwoda, D Melnychuk, L … - Journal of Clinical Oncology, 1999 - jcojournal.org
... MV) in patients with metastatic breast cancer (MBC) progressing ... time to progression
(TTP) and overall survival were significantly longer with docetaxel ...

Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel -
IC Smith, SD Heys, AW Hutcheon, ID Miller, S Payne … - Journal of Clinical Oncology, 2002 - jcojournal.org
... SM, Pierga JY, Asselain B, et al: Breast tumours response to ... predicts local and distant
control as well as survival. Eur J Cancer 31A: 1969-1995, 1995[CrossRef ...

… Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First- … -
M Marty, F Cognetti, D Maraninchi, R Snyder, L … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... HER2-positive MBC, offering a significant survival benefit as ... as a higher rate and
longer duration of ... treatment of patients with HER2-positive breast cancer. ...

Source: Google Scholar

Breast cancer survival longer with Taxotere: study

Last Updated: 2007-12-13 16:47:50 -0400 (Reuters Health)

By Martha Kerr

NEW YORK (Reuters Health) - The long-term findings of a large, multicenter study show that breast cancer survival is significantly improved and side effects are significantly less severe with Taxotere (also called docetaxel) than with Adriamycin (also called doxorubicin).

The findings "have the potential to be practice-changing," principal investigator Dr. Stephen Jones of the US Oncology Medical Center in Houston, Texas told Reuters Health.

Jones presented his group's findings today, the opening day of the San Antonio Breast Cancer Symposium.

The trial involved 1,016 women with breast cancer who had complete surgical excision of the primary tumor. In approximately half of the women, the cancer had not spread to the lymph nodes.

Between June 1997 and December 1999, women were randomly assigned to four cycles of Taxotere plus cyclophosphamide or four cycles of standard therapy with Adriamycin plus cyclophosphamide, administered by infusion every 3 weeks as adjuvant or "add-on" chemotherapy.

Radiation therapy and tamoxifen were given after completion of chemotherapy for patients with so-called hormone receptor-positive disease.

There was a significant survival advantage with Taxotere, Jones announced. "Stated another way, these women had a 31 percent lower risk of dying during follow-up" than those receiving the gold standard, he said.

Taxotere has the "added advantage of fewer and less severe adverse effects," Jones said. Adriamycin has a significant risk of cardiac toxicity, especially in older women. It is also associated with some types of leukemia, he explained.

Taxotere does have some side effects, however. It can still cause nausea and vomiting and hair loss, "but this is not as severe as with (Adriamycin)," the Houston investigator said. "We have shown that a lot of women with early breast cancers don't have to receive Adriamycin-based regimens."

Taxotere plus cyclophosphamide "would appear to be the new standard of care for node-negative women and for those with involvement of up to three local nodes...We don't have a lot of information on women with more than four positive nodes," Jones acknowledged.

"Now that we can see this survival advantage, we can incorporate this regimen into other treatment regimens with other agents," Jones added.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.